Anti-RPS6 Antibody (MA4974) Research Guide

Executive Summary. The Anti-RPS6 (7B10) Mouse Monoclonal Antibody, catalog MA4974, targets the 40S ribosomal protein S6 (RPS6) and is supplied as a mouse IgG1 monoclonal antibody with clone designation AP-11A5B10, according to the product information. The reagent is reported to react with human, mouse, rat, and monkey RPS6 proteins, which supports comparative work across these species when the assay is independently validated. The product is suitable for Western blot, immunocytochemistry/immunofluorescence, and immunoprecipitation, but its listed applications do not by themselves establish performance in every sample type. The cited PDAC study connects LRRC8A–Caveolin-1 signaling with KRAS/EGFR activity, ribosome biogenesis, global protein synthesis, and tumor-cell growth; that study provides pathway context rather than direct validation of MA4974 (Ye et al., 2026).

Biological Rationale

RPS6 is a component of the 40S ribosomal subunit. The protein is also a phosphoprotein associated with regulated translation and growth-related signaling. UniProt identifies human RPS6 as 40S ribosomal protein S6, while the product description emphasizes its involvement in selective translation of mRNA classes (UniProt P62753; product information).

This biology makes RPS6 useful as a protein-level readout in experiments that examine cell growth, proliferation, translation, or ribosome-associated signaling. A signal detected by an RPS6 antibody indicates the presence or distribution of the target under the tested conditions. It does not, without additional controls, prove increased ribosome production, increased translation, or a specific phosphorylation event.

The reference study provides a relevant cancer-biology framework. Ye and colleagues report that LRRC8A, the core subunit of volume-regulated anion channels, supports pancreatic ductal adenocarcinoma progression. Their functional data link LRRC8A and Caveolin-1 to membrane organization, KRAS/EGFR signaling, nucleolar ribosome biogenesis, global protein synthesis, and volumetric expansion during S phase (reference study). An RPS6 antibody for cell signaling research can therefore complement pathway perturbation experiments, but it should be interpreted as one molecular measurement within a broader assay panel.

Mechanism of Action of Anti-RPS6 (7B10) Mouse Monoclonal Antibody

For this product, mechanism of action means reagent binding rather than therapeutic pharmacology. The antibody is designed to bind RPS6. Its immunogen is a recombinant full-length human S6 ribosomal protein. The antibody is affinity purified, unconjugated, unmodified, and assigned the IgG1 isotype. These attributes define the reagent format and determine how it should be detected or recovered in an experiment (MA4974 product page).

The product description does not identify the epitope sequence. It also does not state that clone AP-11A5B10 is phospho-specific. Researchers should therefore avoid labeling the reagent as a phospho-RPS6 antibody unless an independent validation establishes that property. For total-protein Western blot, ICC/IF, or IP, assay-specific optimization remains necessary.

The mouse origin matters for experimental design. A compatible anti-mouse secondary antibody is generally required for indirect detection of an unconjugated primary antibody in Western blot or immunofluorescence. In immunoprecipitation, the host species and IgG1 isotype can affect choices of capture resin, pre-clearing strategy, and immunoglobulin controls. These are workflow considerations, not claims that every secondary antibody or resin will perform equivalently.

Evidence & Benchmarks

The following claims separate product specifications from findings in the reference study. The study did not test the MA4974 antibody as a product-performance benchmark.

1. LRRC8A was identified as a central regulator of cell-volume homeostasis and PDAC progression through bioinformatic and functional analyses DOI: 10.1038/s41388-026-03864-z
2. Genetic silencing or pharmacological inhibition of LRRC8A reduced proliferation-associated volumetric expansion during S phase in the reported PDAC models DOI: 10.1038/s41388-026-03864-z
3. Co-immunoprecipitation followed by mass spectrometry identified Caveolin-1 as a protein complex partner of LRRC8A in the reference study DOI: 10.1038/s41388-026-03864-z
4. Disruption of LRRC8A was associated with lower Caveolin-1 levels, impaired KRAS and EGFR oncogenic signaling, and reduced ribosome biogenesis and global protein synthesis DOI: 10.1038/s41388-026-03864-z
5. The MA4974 product is listed for Western blot, ICC/IF, and immunoprecipitation and is reported to recognize human, mouse, rat, and monkey proteins product information
6. The supplied buffer contains PBS, 50% glycerol, 0.5% BSA, and 0.02% sodium azide at pH 7.3; the listed storage condition is −20°C product information

Applications, Limits & Misconceptions

Recommended research uses

In Western blot, this RPS6 monoclonal antibody can be used to assess RPS6 abundance in lysates. A Western blot result should be interpreted with loading controls, a molecular-weight reference, and positive and negative biological controls. If the experimental question concerns phosphorylation, a phospho-specific reagent or orthogonal phosphorylation assay is required unless the product has been separately validated for that purpose.

In ICC/IF, the antibody can support imaging of RPS6 distribution in fixed cells. Signal localization should be assessed with no-primary controls, secondary-only controls, and, where possible, target knockdown or knockout controls. Antigen retrieval, fixation chemistry, permeabilization, and secondary-antibody cross-reactivity can change apparent signal.

In immunoprecipitation, the antibody can be evaluated for RPS6 enrichment from a compatible lysate. Co-recovered proteins should not automatically be called direct interactors. Reciprocal IP, unrelated-IgG controls, input samples, and nuclease or detergent controls may help distinguish complex association from nonspecific carryover.

These uses make the reagent relevant to an RPS6 antibody for ribosome biogenesis studies, an RPS6 antibody for cancer biology research, and an RPS6 antibody for cell proliferation assays. The antibody is also an unconjugated antibody for research, so detection chemistry must be selected separately.

Common Pitfalls or Misconceptions

• Total RPS6 is not automatically phospho-RPS6. The product description does not state phospho-site specificity. Do not infer pathway activation from total RPS6 signal alone.
• RPS6 detection is not a complete ribosome-biogenesis assay. Ribosome production and translation require complementary measurements. The cited PDAC study reports pathway-level findings, not a universal interpretation for every RPS6 blot.
• Listed species reactivity is not universal sample validation. Human, mouse, rat, and monkey reactivity is reported, but tissue, fixation, lysis, and processing conditions can alter performance.
• IP suitability does not prove a direct protein interaction. A co-immunoprecipitated protein may be part of a larger complex or may result from nonspecific binding.
• The reagent is not a diagnostic or therapeutic product. It is intended for scientific research use only and should not be used for medical diagnosis or treatment.

Workflow Integration & Parameters

A practical workflow begins by defining whether the endpoint is total RPS6 abundance, cellular distribution, or biochemical enrichment. The same primary antibody may require different optimization for denatured lysate, fixed cells, or native IP material. Use the product-listed applications as a starting scope rather than as a substitute for assay validation.

Protocol Parameters

• Antibody identity: Use Anti-RPS6 (7B10) Mouse Monoclonal Antibody, catalog MA4974, clone AP-11A5B10, for target-specific assay development.
• Sample species: The product is reported as reactive with human, mouse, rat, and monkey proteins; confirm signal in the exact tissue, cell line, and preparation used.
• Storage: Store at −20°C as listed by the product information, and avoid repeated freeze-thaw cycles.
• Formulation: The liquid buffer contains PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide at pH 7.3.
• Working concentration: Use the concentration printed on the received label. Optimize dilution or input empirically because a universal working concentration is not supplied in the dossier.
• Application selection: Evaluate the reagent in WB, ICC/IF, or IP according to the intended endpoint. Keep protocol-specific dilution, incubation time, blocking, and wash conditions in the laboratory record.
• Shipment and receipt: The product is shipped on blue ice. Inspect the container and document receipt before placing it at the recommended storage temperature.
• Stability planning: The listed shelf life is 12 months from receipt. Use the lot label and institutional inventory record for expiration control.

For Western blot, include a positive lysate and a loading control. For ICC/IF, include a no-primary control and verify secondary-antibody specificity. For IP, retain input and flow-through samples and include an unrelated mouse IgG control. These controls establish assay behavior; they do not replace genetic or orthogonal target validation.

Related resources

The guide Applied Workflows with Anti-RPS6 Antibody in Ribosome Biogenesis emphasizes workflow execution and troubleshooting. This article extends that discussion by separating total-RPS6 detection from claims about phosphorylation, ribosome biogenesis, and pathway causality.

The article LRRC8A–Caveolin-1 Axis Drives Ribosome Biogenesis in PDAC summarizes the PDAC mechanism. This article clarifies how an RPS6 assay can be integrated as a protein-level readout without treating the antibody as direct evidence for the LRRC8A–Caveolin-1 interaction.

Conclusion & Outlook

MA4974 is a mouse IgG1 Anti-RPS6 antibody configured for WB, ICC/IF, and IP research. Its defined immunogen, host species, formulation, storage condition, and listed cross-species reactivity make it suitable for structured assay development when accompanied by application-specific controls. The product page provides the operational specifications for the Anti-RPS6 (7B10) Mouse Monoclonal Antibody.

The reference study shows that LRRC8A–Caveolin-1 signaling is associated with oncogenic signaling, ribosome biogenesis, protein synthesis, and PDAC growth. A reasonable experimental outlook is to test RPS6 measurements alongside defined pathway perturbations and orthogonal readouts. That approach can strengthen interpretation while preserving the key boundary: antibody signal is evidence about RPS6 detection under specified conditions, not proof of every downstream biological process.